Chroma Dex achieves new regulatory milestones in the European Union and Australia

摘要

ChromaDex Corp. has received regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to consumers in both the European Union and in Australia. ChromaDex received its listing number for Tru Niagen® on the Australian Registry of Therapeutic Goods (ARTG) on January 8,2020. The Company also received authorization to sell its patented nicotinamide riboside chloride as a novel food in the European Union on January 10, 2020. As the regulatory applicants and innovators, ChromaDex benefits from market exclusivity in Australia until December 2021 and market exclusivity in the EU until February 2025.